LENZ Therapeutics (NASDAQ: LENZ) net income
LENZ Therapeutics reported a net loss of $82.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $49.8m. Earnings per share were −$2.85.
LENZ Therapeutics's best year of the last 6 was fiscal 2024. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$82.1m | — | −430.3% | −$2.85 |
| 2024 | −$49.8m | — | — | −$2.34 |
| 2023 | −$70.0m | — | — | −$35.71 |
| 2022 | −$101.1m | — | — | −$1.84 |
| 2021 | −$70.8m | — | — | −$2.45 |
| 2020 | −$68.4m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
LENZ Therapeutics net income compared with its sector
By net income for its latest fiscal year, LENZ Therapeutics ranks 320th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of LENZ Therapeutics, −430.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 318th | Personalis | −$81.3m | −116.7% |
| 319th | Enanta Pharmaceuticals | −$81.9m | −125.4% |
| 320th | LENZ Therapeutics | −$82.1m | −430.3% |
| 321st | Geron | −$83.5m | — |
| 322nd | Aquestive Therapeutics | −$83.8m | −188.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of LENZ Therapeutics
- How much did LENZ Therapeutics earn in fiscal 2025?
- LENZ Therapeutics reported a net loss of $82.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $49.8m.
- What are the earnings per share of LENZ Therapeutics?
- They were −$2.85 in fiscal 2025, compared with −$2.34 in fiscal 2024.
- Where does LENZ Therapeutics rank in its sector by net income?
- It ranks 320th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for LENZ Therapeutics come from?
- From the annual report (Form 10-K) that LENZ Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that LENZ Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on LENZ Therapeutics: the LENZ Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.